Manorama Industries Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Revenue surged 69% YoY to INR 771 crores, driven by strong demand across domestic and export markets for the company's specialty fats portfolio.
• EBITDA margin expanded 870 bps YoY to 24.8%, even after a INR 15.4 crores ESOP provision, as operating leverage and product mix shift toward high-value CBE kicked in.
• CBE contribution tripled from 10% to 30% of sales, anchoring a structural margin uplift that management insists is sustainable and not a commodity-cycle windfall.
• New 25,000-ton fractionation plant hit ~60% utilization in Q4, and combined utilization is guided to 75-85% in FY26, setting up another year of volume-led operating leverage.
• What to watch next quarter: Whether the INR 1,050+ crore FY26 revenue target stays on track as Q1 volumes seasonally dip, the pace of debt reduction from peak working-capital levels, and the Board's approval of the forward/backward integration capex plan.

Revenue Growth & Volume Drivers

• Top-line breakout: FY25 revenue hit INR 771 crores, a 69% YoY jump, with management guiding to INR 1,050+ crores in FY26, implying 35-40% growth split roughly 25-30% from volume and 5-10% from price realization.
• Capacity is the engine: The legacy 15,000-ton plant ran at ~100% utilization throughout the year, while the new 25,000-ton SF2 unit ramped from zero to ~60% utilization by Q4, delivering 3,750 metric tons of quarterly volume from that line alone. Combined utilization for FY25 was ~62.5%, leaving a clear runway to the 75-85% guided for FY26.
• Volume mix is shifting up the value chain: Stearin contributed 7,000 tons and CBE 4,500 tons for the full year, translating to roughly 30% Stearin and 20% CBE on a volume basis. Management expects CBE's share of sales to move beyond 30% in FY26.
• Geographic expansion is early-stage: New subsidiaries in West Africa, UAE and Brazil are meant to deepen global market presence, with the Latin American opportunity alone sized at 25,000 to 30,000 tons, a fragmented landscape that will take time to build.

Ashish Saraf: "Going ahead, the combined capacity utilization for financial year '26 is projected at nearly approximately 75% to 85%. We anticipate achieving greater operational efficiencies and cost optimization through improved utilization of our new fractionation capacity in financial year '26. We are eyeing to achieve INR 1,050 crores top line in financial year '26."

Margin Structure & Sustainability

• The 870 bps margin walk: EBITDA margin moved from ~16.1% in FY24 to 24.8% in FY25, with management attributing the expansion to scale, volume-led growth, product mix enrichment, price growth, operational efficiency and economies of scale, not one-off items.
• CBE is the mix driver: CBE's contribution to sales rose from 10% to 30% over the year, and because every value-added product (Stearin, CBE, specialty fats, butter) carries higher unit margins than base fractions, the mix shift mechanically lifts blended profitability.
• Operating leverage still has room: With 40,000 tons of total capacity running at ~65% combined utilization in FY25, the guided step-up to 75-85% in FY26 implies incremental volumes will absorb fixed costs further, supporting margin resilience even as employee expenses are set to rise 5-10% or more to fund market-share expansion.
• Management is guarded on a specific margin number: When pressed for a second-half margin guide, leadership deflected to general statements about operational excellence and value creation, declining to commit to a range. The company's stance is that margins will naturally reflect performance over time, with updates provided quarter-on-quarter.
• Historical context matters: Margins compressed during 2021-2023 because the company was building out capex that nearly tripled capacity from 15,000 tons, all during the COVID period. That investment cycle is now behind, and the current margin profile reflects the harvest phase.

Ekta Soni: "So looking ahead, we remain confident in the structural strength of our business model and our ability to sustain healthy margins."

CBE: The Specialty Play, Not a Commodity Bet

• Pricing is contractual, not spot-driven: CBE contracts are typically one-year fixed-price agreements in the \$5,000 to \$6,000 per ton range, insulating the business from quarterly commodity swings. New contracts continue to be signed in that same band.
• Cocoa butter prices are an indirect tailwind, not a direct link: Cocoa butter trades at \$14,000-\$20,000 per ton versus CBE at \$5,000-\$6,000. Management acknowledges an indirect relationship but stresses the pricing dynamics differ significantly: CBE is bought for compatibility and functional properties, not as a simple cocoa butter substitute, so the two do not move in lockstep.
• Demand is structural, not opportunistic: Customers have structurally shifted demand toward conventional items like CBE, and the product is customized for each client's tailor-made specifications. The business runs on long-term contracts with chocolate majors to ensure their factories do not stop, making it a planned, recurring revenue stream rather than a commodity-trading opportunity.
• Competitive moat is real: Management positions Manorama among the top three or four players globally, noting that big companies depend on its supplies and that the firm is gaining recognition and awards. The niche, relationship-driven nature of CBE supply creates barriers to entry that commodity markets lack.

Ashish Saraf: "So basically, commodity or this is not -- then these products are used in the various serious food applications, especially the chocolate industry. So, these all are mostly on planned basis so that their factories don't stop, they continuously receive the materials. Maximum business is on the long-term contracts."

Balance Sheet & Working Capital

• Receivables spike is seasonal, not structural: Balance-sheet date receivables stood at 50 days, but the company-wide average is 30 days, well within agreed customer terms. The quarter-end number reflects timing, not deterioration.
• Inventory days are coming down: Management is targeting a reduction from ~150 days to 120-140 days, with efforts on inventory management expected to yield positive outcomes.
• Peak working capital requirement is behind: The company believes the high-water mark for working capital has passed, and incremental debt will keep improving from here. The endeavor is to reduce net debt, though no specific FY26 net-debt number was provided.
• Capex funding will lean on internal accruals: The company has healthy internal accruals to fund the forward and backward integration projects, but management will confirm the financing mix only once the Board approves the capital expenditure plan.

Capex & The Next Growth Leg

• Five projects announced last quarter covering forward integration and backward integration, with a stated priority on projects that can be completed in less than three years. The company has shared a 3-to-5-year roadmap with shareholders.
• Board approval is the gating item: The projects are at an advanced drawing and planning stage, but management expects it will take a quarter or more to secure Board approval, after which a comprehensive report with a detailed financial plan will be filed with the exchanges. Construction is hoped to start this year.
• Margin impact is an open question: When asked whether the new expansion will hurt margins, management said it is too early to say, given the projects are still being defined and prioritized for sub-three-year completion timelines.

Ekta Soni: "It will take a quarter more or more to get the things approved from our Board on our capital expenditure plan."

Risks & Pushback

• Margin guidance remains a black box: Across multiple analyst attempts to extract a specific margin range or second-half guiding principle, management consistently deflected to qualitative statements about operational excellence and value creation, offering only to update quarter-on-quarter.
• CBE pricing history is opaque: When asked for CBE contractual price growth over the last three years, management said prices are growing substantially year-by-year but declined to provide a specific number or growth rate. A request for last year's corresponding sales pricing was deferred to an offline conversation.
• Cocoa-CBE correlation is acknowledged but unquantified: Management stated cocoa butter and CBE prices are not directly correlated but indirectly are, yet declined to provide a ratio or sensitivity framework, citing the fundamentally different pricing dynamics.
• New-customer margin compromise is a live question: An analyst asked whether adding new customers would dilute margins or ROC; management gave a non-specific answer, stating generally that Manorama's policy is not to compromise but acknowledging that different specifications and terms apply to each customer.
• FSSAI 5% rule remains an unquantified demand driver: When asked what percentage of the regulatory allowance for CBE in chocolate the industry has reached, management noted demand is much more than 5% but did not provide the actual penetration figure.

Ashish Saraf: "Sir, this is business and business always has risk. But as such, we don't see immediate any risk perceived in the current, but business is business, sir, we cannot guarantee anything."

Guidance & Commitments

Key Metrics